← Russell 3000 cross-section

IRMD IRADIMED CORP

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$1.1bn
Revenue TTM
$86m
Net income TTM
$23m
Free cash flow
$25m
Composite score
54.9
Sector rank
#1971

Valuation

P / E
48.5
EV / EBITDA
36.3
EV / sales
12.3
FCF yield
2.25%
Earnings yield vs 10-yr
-2.66pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
26.7%
EBITDA margin
33.8%
ROE
22.7%
ROIC
64.6%
Revenue growth
11.2%

Insider activity, last 90 days

Net open-market
$-0.51m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As of June 30, 2026, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the 2025 Annual Report. Results of Operations The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Comparison of the Three Months Ended June 30, 2026 and 2025 Revenue by Geographic Region Revenue by Type For the three months ended June 30, 2026, total revenue increased by $0.1 million, or 0.5%, to $20.5 million from $20.4 million for the same period in 2025. …IRADIMED CORP, 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →